Jakafi PV launch pushes up Incyte's 1Q sales
This article was originally published in Scrip
Executive Summary
Incyte's AK 1 and 2 tyrosine kinase inhibitor, Jakafi (ruxolitinib), has beaten expectations in the first quarter of 2015 following the launch of the product in new indication polycythemia vera.
You may also be interested in...
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.